Abstract
Therapies approved for solid tumors by the FDA from 2016 to 2017 have transformed the way clinicians practice medicine. Dr. Li from the University of New England College of Pharmacy provides the latest clinical trial data and insights on the emergence of new drug classes such as PARP inhibitors and PD-1/PD-L1 inhibitors.
